Cas:33843-21-9 2,2,3-trimethylcyclopent-3-ene-1-carbaldehyde manufacturer & supplier

Chemical Name:2,2,3-trimethylcyclopent-3-ene-1-carbaldehyde

CAS.NO:33843-21-9

Synonyms:campholytic aldehyde;2,2,3-TRIMETHYL-3-CYCLOPENTENE-1-ACETALDEHYDE;2,2,3-trimethylcyclopent-3-enecarbaldehyde

Molecular Formula:C₉H₁₄O

Molecular Weight:138.20700

HS Code:2912299000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:173.253ºC at 760 mmHg

Density:0.953

Index of Refraction:1.509

PSA:17.07000

Exact Mass:138.10400

LogP:2.17770

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like campholytic aldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2,3-trimethylcyclopent-3-enecarbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2,3-trimethylcyclopent-3-enecarbaldehyde Use and application,campholytic aldehyde technical grade,usp/ep/jp grade.

Related News: When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant. 2,2,3-trimethylcyclopent-3-ene-1-carbaldehyde manufacturer From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances). 2,2,3-trimethylcyclopent-3-ene-1-carbaldehyde supplier Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported. 2,2,3-trimethylcyclopent-3-ene-1-carbaldehyde vendor Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported. 2,2,3-trimethylcyclopent-3-ene-1-carbaldehyde factory Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.